Despite a daily loss of 5.03% and a 3-month gain of 18.51%, Axonics Inc (NASDAQ:AXNX) recorded a Loss Per Share of 0.67. This raises the question - is the stock significantly undervalued? In this ...

On September 22, 2023, Axonics Inc (NASDAQ:AXNX) reported a 1.95% daily loss, bringing its 3-month gain to 8.53%. Despite a Loss Per Share of $0.67, the question arises: is the stock significantly ...

Sept 19 (Reuters) - Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's (MDT.N), opens new tab patent rights in nerve-stimulation ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along ...

Boston Scientific Corporation (NYSE:BSX) has agreed to acquire Axonics Inc (NASDAQ: AXNX) for $71 in cash per share, representing an enterprise value of approximately $3.4 billion and an equity value ...

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...

Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion. It’s the first billion-dollar medical device deal of 2024 ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. By way of example, Axonics (NASDAQ:AXNX) has seen its share price ...

Axonics is a medical device company that focuses on bladder and bowel dysfunction therapies. The company also upgraded its annual revenue guidance. Axonics recently won on appeal in a patent fight ...